Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-03-06
1998-07-28
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 17, 514 18, 530317, 530322, 530329, 530330, 530331, A61K 3800
Patent
active
057863326
ABSTRACT:
The present invention relates to novel peptides that are potent cytokine restraining agents. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a cytokine restraining agent. Administration of such a cytokine restraining agent to a subject restrains, but does not necessarily suppress, cytokine activity completely. Thus, the present invention provides a method of restraining pathologically elevated cytokine activity in a subject. The invention also provides methods of treating disuse deconditioning and diseases mediated by nitric oxide and cytokines, such as diabetes and glomerulonephritis, a method of organ protection, a method of organ protection, and a method of reducing the negative side effects of cancer chemotherapy, such as nephrotoxicity.
REFERENCES:
patent: 4457864 (1984-07-01), Hruby et al.
patent: 4485039 (1984-11-01), Hruby et al.
patent: 4649191 (1987-03-01), Hruby
patent: 4866038 (1989-09-01), Hruby et al.
patent: 4918055 (1990-04-01), Hruby et al.
patent: 5028592 (1991-07-01), Lipton
patent: 5049547 (1991-09-01), Hruby et al.
patent: 5157023 (1992-10-01), Lipton
patent: 5408038 (1995-04-01), Smith et al.
patent: 5420109 (1995-05-01), Suto et al.
patent: 5462927 (1995-10-01), Moreau et al.
Yajima et al., "Studies on peptides. XI. The effect on melanotropic activity of altering the arginyl residue in L-histidyl-L-phenylalanyl-L-arginyl-L-tryptophylglycine" Biochim. Biophys. Acta, 127:545-549 (1966).
Chemical abstract No. 16789n, p. 1613, vol. 66, No. 5, Jan. 30, 1967.
Abou-Mohamed et al., "HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but no in vitro". J. Pharmacol. Exp. Ther., Abstract No. 959276, 275(2) :584-591 (Jul. 21, 1995).
Mackensen et al., "Treatment of cancer patients with endotoxin induces release of endogenous cytokines." Pathobiol., 59:264-267 (1991).
Mackensen et al., "Modulating activity of interferon-.gamma. on endotoxin-induced cytokine production in cancer patients." Blood, 78(12):3254-3258 (1991).
Rabinowitz et al., "Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support." Blood, 81(9) :2452-2459 (1993).
Creekmore et al., "Strategies for clinical monitoring of therapeutic trials." Manual of Clin. Lab. Immunol., 915-922 (1992).
Thavasu et al., "Measuring cytokine levels in blood: Importance of anticoagulans, processing, and storage conditions." J. of Immunol. Methods, 153:115-124 (1992).
Payne et al., "Hypothalamic releasing hormones mediating the effects of interleukin-1 on sleep." J. of Cell. Biochem., 53:309-313 (1993).
Tilg et al., "Interleukin-6 (IL-6) as an Anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55." Blood, 83(1):113-118 (1994).
Wong et al., "Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis In Vitro and In Vivo." J. Exp.Med., 177:775-781 (1993).
Gorgen et al., "Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-.alpha.. " J. of Immonol., 149:918-924 (1992).
Dinarello et al., "The role of interleukin-1 in disease." New England J. Med., 328:106-113 (1993).
Richar and Lipton, "Effect of .alpha.-MSH 11-13 (Lysine-Proline-Valine) on Fever in the Rabbit." Peptides, 5:815-817 (1984).
Deeter et al., "Antipyretic properties of centrally administered .alpha.-MSH fragments in the rabbit." Peptides9:1285-1288 (1989).
Sugg et al., "D-Isomeric replacements within the 6-9 core sequence of a the solution conformation of .alpha.-Melanotropin." Biopolymers, 25:2029-2042 (1986).
Norlund, James J., ".alpha.-Melanocyte-stimulating hormone a ubiquious cytokine with pigmenting effects." J. Amer. Med. Assoc., 226:2753-2754 (1991).
Levine et al., "Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin." J. Amer. Med. Assoc., 266:2730-2736 (1991).
Al-Obeidi et al., "Design of a new class of superpotent cyclic .alpha.-melanotrophins based on quenched dynamic simulations." J. Am. Chem. Soc., 111:3413-3416 (1989).
Poole et al., "Peripheral analgesic activities of peptides related to .alpha.-melanocyte stimulating hormone and interleukin-1.beta..sup.193-195." Br. J. Pharmacol. 106:489-492 (1992).
Follenfant et al., "Inhibition by neuropeptides of interleukin-1 .alpha.-induced prostaglandin-independent hyperalgesia.", 98:41-43 (1989).
Rivier et al., "In the mouse, the activation of the hypothalamic-pituitary-adrenal axis by a lipopolysaccharide (Endotoxin) is mediated through interleukin-1." Endocrinology, 125(6) :2800-2805 (1989).
Vinegar et al., "Biphasic development of carrageenin edema in rats." J. of Pharmacol and Exper. Therapeutics, 166(1) ;96-103 (1969).
Vinegar et al., "Pathway to carrageenan-induced inflammation in the hind limb of the rat." Federation Proc., 46:118-126 (1987).
Hiltz and Lipton, "Alpha-MSH peptides inhibit acute inflammation and contact sensitivity." Peptides, 11(5) 979-982 (1990).
Ray et al., "Cytokines and their receptors: Molecular mechanism of interleukin-6 gene repression by glucocorticoids." J. Am. Soc. Nephrol., 2:s214-s221 (1992).
Karkar et al., "Passive immunization against tumor necrosis factor-alpha (TNF-.alpha.) and IL-1.beta.protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats." Clin. Exp. Immunol., 90:312-318 (1992).
Ulich et al., "Indotoxin-induced cytokine gene expression in-vivo". Am. J. of Pathol., 141(1) :61-68 (1992).
Jansen et al., "Induction of nitric oxide synthase in rat immune complex glomerulonephritis." Kidney Int'l., 45 :1215-1219 (1994).
Yajima et al., Chem. Pharm. Bull., 15(4), 504-510. 1967.
Dayhoff, M. , Atlas of Protein Sequence and Structure, vol. 5, 1972, p. 96.
Girten Beverly E.
Houghten Richard A.
Loullis Costas C.
Suto Mark J.
Tuttle Ronald R.
Delacroix-Muirheid C.
Trega Biosciences, Inc.
Tsang Cecilia J.
LandOfFree
Cytokine restraining agents and methods of use in pathologies an does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cytokine restraining agents and methods of use in pathologies an, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cytokine restraining agents and methods of use in pathologies an will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-23636